Nevada Medicaid and GLP-1 coverage

One drug list now binds every Nevada Medicaid plan. The state's own announcement states that "As of January 1, 2026, Nevada Medicaid has transitioned to a Single Preferred Drug List (sPDL)" and that "The sPDL is used statewide, which means every Medicaid plan follows the same list." It also describes a "Legacy Coverage Phase" running "from January 1, 2026, through June 30, 2026" during which members could keep filling a medication that had become non-preferred.

Nevada Medicaid, Web Announcement 3916, effective January 2026 · source

The statewide drug list has no anti-obesity class. Its "Incretin Mimetics and Combinations" class lists Byetta, Ozempic, Rybelsus, Trulicity and Victoza as preferred and Bydureon BCise, exenatide, liraglutide, Mounjaro, Soliqua and Xultophy as non-preferred, and routes every one of them to "MSM 1200 - Appendix A section: KK. Incretin Mimetics." Wegovy, Zepbound and Saxenda are named nowhere in the document, under this or any other heading — a full text extraction of the 183,255-character file returns no occurrence of any of the three, nor of the words obesity or weight.

Nevada Medicaid and Nevada Check Up Preferred Drug List, effective November 2025 · source

The exclusion is in the manual, not in a formulary footnote. Under the heading "Excluded," the state writes: "Nevada Medicaid will not reimburse for the following pharmaceuticals:" and the first item on the list is "Agents used for weight management." The same section also excludes fertility agents, cosmetic and hair-growth agents, and drugs for erectile dysfunction.

Nevada Medicaid, Medicaid Services Manual Chapter 1200 — Prescribed Drugs, Section 1203, effective August 2026 · source

The diabetes criteria say the quiet part outright. Approval under the Incretin Mimetics criteria requires that the drug be prescribed either as an "Adjunct to diet and exercise to improve glycemic control in recipients with type 2 diabetes mellitus (T2DM)" or to "Reduce the risk of major adverse cardiovascular events ... in recipients with type 2 diabetes and established cardiovascular disease," plus "Documentation of A1C lab results within past 180 days" and, in its own numbered clause, that the "Medication is not being prescribed for weight loss in absence of T2DM indication." Approval runs one year.

Nevada Medicaid, Medicaid Services Manual Chapter 1200, Appendix A section KK (Incretin Mimetics), effective August 2026 · source

Wegovy has a heart-risk door, and it is specialist-gated. The exception criteria require that the "Medication is being prescribed for risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight," that the recipient be 18 or older with a "body mass index (BMI) ≥27 kg/m2," and that "Wegovy® must be prescribed by, or in consultation with, a cardiologist or vascular specialist." Established disease means a prior heart attack, a prior stroke, symptomatic peripheral arterial disease, or a specialist's documentation. The recipient "must not have type 1 or type 2 diabetes" and "must not be utilizing another glucagon-like peptide (GLP-1) therapy." Initial approval is six months, and renewal turns on reaching the 2.4 mg weekly injection dose (or 25 mg daily for the tablet) or the prescriber explaining why that dose is not appropriate.

Nevada Medicaid, Medicaid Services Manual Chapter 1200, Appendix A section KK, exception criteria for Wegovy, effective August 2026 · source

Zepbound's only door is sleep apnea, and the state wants a sleep study. Approval requires an adult 18 or older and that the "Medication is being prescribed for moderate to severe obstructive sleep apnea (OSA) in adults with obesity," defined as "15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study from a certified or accredited sleep disorder facility" — or five or more events plus a listed symptom, or, where a facility study is not possible "due to immobility, safety, or critical illness," a diagnosis from a board-certified sleep specialist or pulmonologist. The recipient must be "fully compliant with ongoing treatment(s) for the underlying airway obstruction (e.g., CPAP, BiPAP), unless there is rationale from provider as to why treatment is not indicated," must have a "body mass index (BMI) >30 kg/m2," and "must not have type 1 or type 2 diabetes." Initial and renewal approvals are six months each.

Nevada Medicaid, Medicaid Services Manual Chapter 1200, Appendix A section KK, exception criteria for Zepbound, effective August 2026 · source

A third door runs through the liver. Nevada's MASH criteria cover Wegovy for a recipient 18 or older with "a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stage 2 or 3" confirmed by liver biopsy, vibration-controlled transient elastography, or magnetic resonance elastography, who is "not utilizing another glucagon-like peptide (GLP-1) therapy." Renewal requires the FDA maintenance dose of 2.4 mg weekly, or 1.7 mg where the dose was reduced for intolerance. The same section makes Rezdiffra the second choice: it is approved only where the recipient "has inadequate response, intolerance, or contraindication to Wegovy® (semaglutide) for MASH treatment" or a specialist justifies expecting Wegovy to fail.

Nevada Medicaid, Medicaid Services Manual Chapter 1200, Appendix A section G (Metabolic Dysfunction-Associated Steatohepatitis), effective August 2026 · source

Nevada gives recipients 90 calendar days and counts from the date on the letter. Its hearings chapter states that "The request must be received by the Nevada Medicaid Hearings Office within 90 calendar days from the date on the Notice of Decision (NOD) issued by Nevada Medicaid or Managed Care Entity (MCE), unless a recipient can substantiate 'good cause' for not doing so. When the deadline falls on a weekend or holiday, the deadline is extended to the next working day." A 2025 law change (Assembly Bill 36) added extenuating circumstances that can excuse a late filing. Note that the date of the request is "the date the request is received," not the date it is sent.

Nevada Medicaid, Medicaid Services Manual Chapter 3100 — Hearings, Section 3104 (Recipient Hearings), effective August 2026 · source

If you are in a managed care plan, the plan's clock comes first and it is shorter. Health Plan of Nevada's Medicaid appeals page tells members "You have the right to file an appeal within 60 days of receiving a notice," and that only afterward — "after all of HPN Medicaid's appeals have been completed" — can a member ask the Nevada Medicaid Hearings Unit for a State Fair Hearing, adding "You must ask for this hearing within 90 days of receiving the final Appeal Notice from HPN Medicaid." Both of the plan's clocks run from receipt of a notice rather than from the date printed on it.

Health Plan of Nevada Medicaid (a Nevada Medicaid managed care plan; this is the plan's own page, not a state rule) · source